200 related articles for article (PubMed ID: 19208459)
1. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
[TBL] [Abstract][Full Text] [Related]
2. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
[TBL] [Abstract][Full Text] [Related]
4. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
5. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
6. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ
Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
9. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.
Hanrahan JP; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Baumgartner RA
COPD; 2008 Feb; 5(1):25-34. PubMed ID: 18259972
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
Rabe KF; Timmer W; Sagkriotis A; Viel K
Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of arformoterol and formoterol in COPD.
Hanania NA; Donohue JF; Nelson H; Sciarappa K; Goodwin E; Baumgartner RA; Hanrahan JP
COPD; 2010 Feb; 7(1):17-31. PubMed ID: 20214460
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
13. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
14. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD.
Terzano C; Petroianni A; Conti V; Ceccarelli D; Graziani E; Sanduzzi A; D'Avelli S
Respir Med; 2008 Dec; 102(12):1701-7. PubMed ID: 18760583
[TBL] [Abstract][Full Text] [Related]
15. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
18. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
20. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.
Salvi S; Brashier B; Gothi D; Karkhanis V; Madas S; Gogtay J; Joshi J
Pulm Pharmacol Ther; 2014 Feb; 27(1):90-5. PubMed ID: 23752057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]